Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

Kumamoto University45 enrolled

Overview

The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Age-related Macular Degeneration

Interventions

BevacizumabDRUG

A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * choroidal neovascularization caused by age-related macula degeneration * no previous treatment * a follow-up at least 12 months * a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart Exclusion Criteria: * choroidal neovascularization caused by other eye diseases * ocular surgery within the past 3 mouths * history of uveitis * intraocular pressure higher than 25 mmHg, or glaucoma * history of systemic or ocular thromboembolic events.

Locations (1)

Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kumamoto University

Kumamoto, Japan

Outcomes

Primary Outcomes

Visual acuity

Time frame: The comparison between baseline and 12-month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.